News for LGVN Stock

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference Longeveron® to Attend BIO International Convention 2025 Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025 Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease Longeveron® to Present at the 37th Annual Roth Conference Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025 Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™ Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025 Longeveron to Present at Biotech Showcase 2025 Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024 Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC) Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference Longeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS) Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024 Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC) Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease Neha Motwani Elected to Longeveron® Board of Directors Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024 Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024 Longeveron® Announces Contract Development and Manufacturing Business and First Contract Longeveron® to Attend BIO International Convention 2024 Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update Longeveron Announces Board of Directors Planned Transitions Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 Longeveron to Present at the Planet MicroCap Showcase Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC) Longeveron Announces Closing of $5.2 Million Public Offering Longeveron Announces Pricing of $5.25 Million Public Offering Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals Longeveron Announces 1-for-10 Reverse Stock Split Longeveron Reports Year-End 2023 Results and Provides Corporate Update Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024 Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™ Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease ExThera Medical Taps Current Board Member and Top Finance Executive to Take the Helm Long-term Survival Data from Longeveron’s ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023 Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ for the Treatment of Mild Alzheimer’s Longeveron Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Longeveron Announces Positive Top-Line Results for Lomecel-B™ in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer’s Disease Longeveron Issues Letter to Stockholders Long-term Survival Data from Longeveron’s ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association Longeveron to Present at the 25th Annual H.C. Wainwright Global Investment Conference Longeveron to Participate in the 149th Annual National Investment Banking Association Conference Longeveron Rights Offering Subscription Period Begins Longeveron Rights Offering Declared Effective and Calendar Finalized Longeveron to Host Key Opinion Leader Event on Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B™ on August 16, 2023 Longeveron Announces Pricing for Rights Offering and Expected Calendar Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update Longeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome Longeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023 Longeveron Appoints Lisa Locklear as Chief Financial Officer Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer Longeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors Longeveron Files Registration Statement for Rights Offering Longeveron Welcomes Three New Prominent Board Members Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results Longeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome Longeveron to Announce First Quarter 2023 Financial Results on May 12, 2023 Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B™ for Aging-Related Frailty in Japan Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023 Longeveron Appoints Wa’el Hashad as Chief Executive Officer Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal UPDATE -- Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones Longeveron to Participate in Upcoming 2022 Investor Conferences Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer’s Disease Longeveron to Announce Third Quarter 2022 Financial Results on November 14, 2022 Longeveron to Present at the Annual Dawson James Small Cap Growth Conference Longeveron Names Jerome Bailey Vice President of Business Operations Longeveron to Present at H.C. Wainwright 24th Annual Global Investment Conference U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeveron’s Lomecel-B™ Product for Treatment of Hypoplastic Left Heart Syndrome (HLHS) in Infants Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy Through Levels of Vascular Biomarker Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results Longeveron Announces Abstract Accepted for Presentation at the Alzheimer’s Association International Conference (AAIC) Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results Longeveron Announces CEO Transition Longeveron to Announce First Quarter 2022 Financial Results on May 13, 2022 Longeveron to Present at Longevity Leaders World Congress; Latinos and Alzheimer’s Symposium; International Frailty and Sarcopenia Research Conference Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer’s Trial Longeveron Expands Executive Leadership Team; Appoints K. Chris Min, M.D., Ph.D. as Chief Medical Officer Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association Longeveron Presents at Second Euro-Geroscience Conference Longeveron to Present at Oppenheimer 32nd Annual Healthcare Conference Longeveron Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress Longeveron to Announce Fourth Quarter and Full Year 2021 Financial Results, on March 11, 2022 Longeveron to Present at Q1 Virtual Investor Summit Conference Longeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directors Longeveron to Participate in Phacilitate Advanced Therapies Week Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease Longeveron to Participate in the H.C. Wainwright BioConnect 2022 Virtual Conference Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS) Longeveron Inc. Announces Closing of a $20.5 Million Private Placement Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement Longeveron Announces Phase 2 Clinical Trial in Japan to Test Safety and Efficacy of Lomecel-B on Aging Frailty Patients U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2021 Financial Results Longeveron to Release Third Quarter 2021 Financial Results and Hold Conference Call on November 12, 2021 Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial Longeveron Announces Activation of Two New Clinical Sites in ELPIS II Trial of Lomecel-B for Hypoplastic Left Heart Syndrome (HLHS) Longeveron to Present at the 2021 Dawson James Securities 6th Annual Small Cap Growth Conference Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity Longeveron Announces Multiple Presentations at the 11th Annual International Conference on Frailty & Sarcopenia Research Longeveron Announces Dr. Jorge Ruiz as Speaker for Roundtable Discussion & Presentation at 2021 International Conference for Frailty & Sarcopenia Research Longeveron Partners with Kinesiometrics to Create and Implement Cutting-Edge Smart Phone App to Measure Physical Responses to Cell Therapy Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients Longeveron to Present at H.C. Wainwright 23rd Annual Global Investor Conference Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial Results Longeveron Announces Topline Results of Phase 2b Study of Lomecel-B for Aging Frailty Longeveron to Release Second Quarter 2021 Financial Results and Hold Conference Call on August 13, 2021 Longeveron Announces First Patient Treated in Phase 2b Hypoplastic Left Heart Syndrome (HLHS) Clinical Study Longeveron Announces Two Abstracts Accepted for Presentation at the Gerontological Society of America 2021 Annual Scientific Meeting Longeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer’s Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer's Association International Conference Longeveron to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Cell Summit Longeveron’s Chairman and Chief Science Officer Invited by National Academy of Medicine to Speak at Longevity Symposium Longeveron Announces the Appointment of Ursula Ungaro to its Board of Directors Longeveron Announces the Hiring of Dan Gincel, Ph.D., as Senior Vice President, Strategic Collaborations & Scientific Affairs Longeveron Inc. Provides Corporate Update and Reports First Quarter 2021 Financial Results Longeveron to Release First Quarter 2021 Financial Results and Hold Conference Call on May 14, 2021 Longeveron Invited to Present at the Benzinga Global Small Cap Conference Longeveron Selected to Present at the 2021 World Stem Cell Summit Longeveron Announces Successful Completion of Phase I/II Clinical Study of Lomecel-B Infusion in Aging Frailty Subjects to Improve Immune Response Following Influenza Vaccination Longeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer’s Disease Longeveron Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results Longeveron Schedules 2020 Fiscal Year End Business Update Conference Call Longeveron Inc. to Present at the Q1 Virtual Investor Summit on March 24 Longeveron Inc. Announces Partial Exercise of Over-Allotment Option in Initial Public Offering Longeveron’s Lomecel-B™ Approved by FDA for Compassionate Use for the Treatment of Child with Hypoplastic Left Heart Syndrome (HLHS) Longeveron and University of Miami Expand Exclusive License Agreement, and Enter into CRADA To Facilitate Future Collaborations Longeveron Expands Enrollment Criteria for its Phase 1 RECOVER Trial Evaluating Lomecel-B Infusion to Treat Acute Respiratory Distress Syndrome due to COVID-19 or Influenza Infection Longeveron Announces Successful Completion of Phase 2b Clinical Study of Lomecel-B Infusion to Treat Aging Frailty Longeveron Announces Successful Completion of Phase 1 Clinical Study of Lomecel-B Intramyocardial Injection in Hypoplastic Left Heart Syndrome Patients CEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & Gerontology Longeveron Inc. Announces the Appointment of Prominent Biotech, Capital Markets and Corporate Finance Executives to the Board of Directors Longeveron Inc. Announces Pricing of an Upsized $26.6 Million Initial Public Offering and Nasdaq Listing